1
|
Kuroki K, Hoang CT, Rogic AM, Rindt H, Simenson A, Noall LG, Bryan JN, Johnson GC, Chu S. Hotspot Exon 15 Mutations in BRAF Are Uncommon in Feline Tumours. Vet Comp Oncol 2024. [PMID: 39015955 DOI: 10.1111/vco.12997] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2024] [Revised: 07/01/2024] [Accepted: 07/02/2024] [Indexed: 07/18/2024]
Abstract
BRAF is one of multiple RAF proteins responsible for the activation of the MAPK cell signalling cascade involved in cell growth, differentiation, and survival. A hotspot BRAFV600E mutation, in exon 15, was determined to be a driver in 100% hairy cell leukaemias, 50%-60% of human melanomas, 30%-50% of human thyroid carcinomas and 10%-20% of human colorectal carcinomas. The orthologous BRAFV595E mutation was seen in 67% and 80% of canine bladder transitional cell carcinomas and prostatic adenocarcinomas, respectively. Since veterinary and human cancers exploit similar pathways and BRAF is highly conserved across species, BRAF can be expected to be a driver in a feline cancer. Primers were developed to amplify exon 15 of feline BRAF. One hundred ninety-six feline tumours were analysed. Sanger sequencing of the 211 bp PCR amplicon was done. A BRAF mutation was found in one tumour, a cutaneous melanoma. The mutation was a BRAFV597E mutation, orthologous to the canine and human hotspot mutations. A common synonymous variant, BRAFT586T, was seen in 23% (47/196) of tumours. This variant was suspected to be a single nucleotide polymorphism. BRAF was not frequently mutated in common feline tumours or in tumour types that frequently harbour BRAF mutations in human and canine cancers. As is seen in canine cancer genomics, the mutational profile in feline tumours may not parallel the histologic equivalent in human oncology.
Collapse
Affiliation(s)
- Kei Kuroki
- Veterinary Medical Diagnostic Laboratory, College of Veterinary Medicine, University of Missouri, Columbia, Missouri, USA
| | - Christine Tran Hoang
- Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, Missouri, USA
| | - Anita M Rogic
- Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, Missouri, USA
| | - Hans Rindt
- Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, Missouri, USA
| | - Angelynn Simenson
- Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, Missouri, USA
| | - Lucie G Noall
- Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, Missouri, USA
| | - Jeffrey N Bryan
- Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, Missouri, USA
| | - Gayle C Johnson
- Veterinary Medical Diagnostic Laboratory, College of Veterinary Medicine, University of Missouri, Columbia, Missouri, USA
| | - Shirley Chu
- Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, Missouri, USA
| |
Collapse
|
2
|
Mochizuki H, Breen M. Sequence analysis of RAS
and RAF
mutation hot spots in canine carcinoma. Vet Comp Oncol 2016; 15:1598-1605. [DOI: 10.1111/vco.12275] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2016] [Revised: 09/13/2016] [Accepted: 09/13/2016] [Indexed: 12/19/2022]
Affiliation(s)
- H. Mochizuki
- Department of Molecular Biomedical Sciences, College of Veterinary Medicine; North Carolina State University; Raleigh NC USA
- Comparative Medicine Institute; North Carolina State University; Raleigh NC USA
| | - M. Breen
- Department of Molecular Biomedical Sciences, College of Veterinary Medicine; North Carolina State University; Raleigh NC USA
- Comparative Medicine Institute; North Carolina State University; Raleigh NC USA
- Center for Human Health and the Environment; North Carolina State University; Raleigh NC USA
- Lineberger Comprehensive Cancer Center; University of North Carolina; Chapel Hill NC USA
| |
Collapse
|
3
|
Adega F, Borges A, Chaves R. Cat Mammary Tumors: Genetic Models for the Human Counterpart. Vet Sci 2016; 3:vetsci3030017. [PMID: 29056725 PMCID: PMC5606576 DOI: 10.3390/vetsci3030017] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2016] [Revised: 08/06/2016] [Accepted: 08/11/2016] [Indexed: 12/18/2022] Open
Abstract
The records are not clear, but Man has been sheltering the cat inside his home for over 12,000 years. The close proximity of this companion animal, however, goes beyond sharing the same roof; it extends to the great similarity found at the cellular and molecular levels. Researchers have found a striking resemblance between subtypes of feline mammary tumors and their human counterparts that goes from the genes to the pathways involved in cancer initiation and progression. Spontaneous cat mammary pre-invasive intraepithelial lesions (hyperplasias and neoplasias) and malignant lesions seem to share a wide repertoire of molecular features with their human counterparts. In the present review, we tried to compile all the genetics aspects published (i.e., chromosomal alterations, critical cancer genes and their expression) regarding cat mammary tumors, which support the cat as a valuable alternative in vitro cell and animal model (i.e., cat mammary cell lines and the spontaneous tumors, respectively), but also to present a critical point of view of some of the issues that really need to be investigated in future research.
Collapse
Affiliation(s)
- Filomena Adega
- Laboratory of Cytogenomics and Animal Genomics (CAG), Department of Genetics and Biotechnology (DGB), University of Trás-os-Montes and Alto Douro (UTAD), Vila Real 5001-801, Portugal.
- Faculty of Sciences, BioISI-Biosystems & Integrative Sciences Institute, University of Lisboa, Campo Grande, Lisboa 1749-016, Portugal.
| | - Ana Borges
- Laboratory of Cytogenomics and Animal Genomics (CAG), Department of Genetics and Biotechnology (DGB), University of Trás-os-Montes and Alto Douro (UTAD), Vila Real 5001-801, Portugal.
- Faculty of Sciences, BioISI-Biosystems & Integrative Sciences Institute, University of Lisboa, Campo Grande, Lisboa 1749-016, Portugal.
| | - Raquel Chaves
- Laboratory of Cytogenomics and Animal Genomics (CAG), Department of Genetics and Biotechnology (DGB), University of Trás-os-Montes and Alto Douro (UTAD), Vila Real 5001-801, Portugal.
- Faculty of Sciences, BioISI-Biosystems & Integrative Sciences Institute, University of Lisboa, Campo Grande, Lisboa 1749-016, Portugal.
| |
Collapse
|
4
|
Crozier C, Wood GA, Foster RA, Stasi S, Liu JHW, Bartlett JMS, Coomber BL, Sabine VS. KRAS Mutations in Canine and Feline Pancreatic Acinar Cell Carcinoma. J Comp Pathol 2016; 155:24-8. [PMID: 27290644 DOI: 10.1016/j.jcpa.2016.05.007] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2015] [Revised: 04/04/2016] [Accepted: 05/07/2016] [Indexed: 12/15/2022]
Abstract
Companion animals may serve as valuable models for studying human cancers. Although KRAS is the most commonly mutated gene in human ductal pancreatic cancers (57%), with mutations frequently occurring at codons 12, 13 and 61, human pancreatic acinar cell carcinomas (ACCs) lack activating KRAS mutations. In the present study, 32 pancreatic ACC samples obtained from 14 dogs and 18 cats, including seven metastases, were analyzed for six common activating KRAS mutations located in codons 12 (n = 5) and 13 (n = 1) using Sequenom MassARRAY. No KRAS mutations were found, suggesting that, similar to human pancreatic ACC, KRAS mutations do not play a critical role in feline or canine pancreatic ACC. Due to the similarity of the clinical disease in dogs and cats to that of man, this study confirms that companion animals offer potential as a suitable model for investigating this rare subtype of pancreatic carcinoma.
Collapse
Affiliation(s)
- C Crozier
- Transformative Pathology Platform, Ontario Institute for Cancer Research, Toronto, Ontario, Canada
| | - G A Wood
- Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada
| | - R A Foster
- Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada
| | - S Stasi
- Transformative Pathology Platform, Ontario Institute for Cancer Research, Toronto, Ontario, Canada
| | - J H W Liu
- Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada
| | - J M S Bartlett
- Transformative Pathology Platform, Ontario Institute for Cancer Research, Toronto, Ontario, Canada
| | - B L Coomber
- Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.
| | - V S Sabine
- Transformative Pathology Platform, Ontario Institute for Cancer Research, Toronto, Ontario, Canada
| |
Collapse
|
5
|
Zorzan E, Hanssens K, Giantin M, Dacasto M, Dubreuil P. Mutational Hotspot of TET2, IDH1, IDH2, SRSF2, SF3B1, KRAS, and NRAS from Human Systemic Mastocytosis Are Not Conserved in Canine Mast Cell Tumors. PLoS One 2015; 10:e0142450. [PMID: 26562302 PMCID: PMC4643045 DOI: 10.1371/journal.pone.0142450] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2015] [Accepted: 10/21/2015] [Indexed: 12/11/2022] Open
Abstract
Introduction Both canine cutaneous mast cell tumor (MCT) and human systemic mastocytosis (SM) are characterized by abnormal proliferation and accumulation of mast cells in tissues and, frequently, by the presence of activating mutations in the receptor tyrosine kinase V-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog (c-KIT), albeit at different incidence (>80% in SM and 10–30% in MCT). In the last few years, it has been discovered that additional mutations in other genes belonging to the methylation system, the splicing machinery and cell signaling, contribute, with c-KIT, to SM pathogenesis and/or phenotype. In the present study, the mutational profile of the Tet methylcytosine dioxygenase 2 (TET2), the isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2), the serine/arginine-rich splicing factor 2 (SRSF2), the splicing factor 3b subunit 1 (SF3B1), the Kirsten rat sarcoma viral oncogene homolog (KRAS) and the neuroblastoma RAS viral oncogene homolog (NRAS), commonly mutated in human myeloid malignancies and mastocytosis, was investigated in canine MCTs. Methods Using the Sanger sequencing method, a cohort of 75 DNA samples extracted from MCT biopsies already investigated for c-KIT mutations were screened for the “human-like” hot spot mutations of listed genes. Results No mutations were ever identified except for TET2 even if with low frequency (2.7%). In contrast to what is observed in human TET2 no frame-shift mutations were found in MCT samples. Conclusion Results obtained in this preliminary study are suggestive of a substantial difference between human SM and canine MCT if we consider some target genes known to be involved in the pathogenesis of human SM.
Collapse
Affiliation(s)
- Eleonora Zorzan
- Department of Comparative Biomedicine and Food Science, University of Padua, Legnaro, Padua, Italy
| | - Katia Hanssens
- Inserm U1068, Centre de Recherche en Cancérologie de Marseille, Signalisation, Hematopoiesis and Mechanisms of Oncogenesis, Centre de référence des mastocytoses, Institut Paoli Calmettes, CNRS, Aix Marseille Université, Marseille, France
| | - Mery Giantin
- Department of Comparative Biomedicine and Food Science, University of Padua, Legnaro, Padua, Italy
| | - Mauro Dacasto
- Department of Comparative Biomedicine and Food Science, University of Padua, Legnaro, Padua, Italy
| | - Patrice Dubreuil
- Inserm U1068, Centre de Recherche en Cancérologie de Marseille, Signalisation, Hematopoiesis and Mechanisms of Oncogenesis, Centre de référence des mastocytoses, Institut Paoli Calmettes, CNRS, Aix Marseille Université, Marseille, France
- * E-mail:
| |
Collapse
|
6
|
MALIGNANT MELANOMA IN THE PENGUIN: CHARACTERIZATION OF THE CLINICAL, HISTOLOGIC, AND IMMUNOHISTOCHEMICAL FEATURES OF MALIGNANT MELANOMA IN 10 INDIVIDUALS FROM THREE SPECIES OF PENGUIN. J Zoo Wildl Med 2014; 45:534-49. [DOI: 10.1638/2013-0207r1.1] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
7
|
Berry CR, Garg P. Perspectives in molecular imaging through translational research, human medicine, and veterinary medicine. Semin Nucl Med 2014; 44:66-75. [PMID: 24314047 DOI: 10.1053/j.semnuclmed.2013.10.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
The concept of molecular imaging has taken off over the past 15 years to the point of the renaming of the Society of Nuclear Medicine (Society of Nuclear Medicine and Molecular Imaging) and Journals (European Journal of Nuclear Medicine and Molecular Imaging) and offering of medical fellowships specific to this area of study. Molecular imaging has always been at the core of functional imaging related to nuclear medicine. Even before the phrase molecular imaging came into vogue, radionuclides and radiopharmaceuticals were developed that targeted select physiological processes, proteins, receptor analogs, antibody-antigen interactions, metabolites and specific metabolic pathways. In addition, with the advent of genomic imaging, targeted genomic therapy, and theranostics, a number of novel radiopharmaceuticals for the detection and therapy of specific tumor types based on unique biological and cellular properties of the tumor itself have been realized. However, molecular imaging and therapeutics as well as the concept of theranostics are yet to be fully realized. The purpose of this review article is to present an overview of the translational approaches to targeted molecular imaging with application to some naturally occurring animal models of human disease.
Collapse
Affiliation(s)
- Clifford R Berry
- Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL.
| | | |
Collapse
|
8
|
Hwang CC, Umeki S, Kubo M, Hayashi T, Shimoda H, Mochizuki M, Maeda K, Baba K, Hiraoka H, Coffey M, Okuda M, Mizuno T. Oncolytic reovirus in canine mast cell tumor. PLoS One 2013; 8:e73555. [PMID: 24073198 PMCID: PMC3779226 DOI: 10.1371/journal.pone.0073555] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2013] [Accepted: 07/21/2013] [Indexed: 02/07/2023] Open
Abstract
The usage of reovirus has reached phase II and III clinical trials in human cancers. However, this is the first study to report the oncolytic effects of reovirus in veterinary oncology, focusing on canine mast cell tumor (MCT), the most common cutaneous tumor in dogs. As human and canine cancers share many similarities, we hypothesized that the oncolytic effects of reovirus can be exploited in canine cancers. The objective of this study was to determine the oncolytic effects of reovirus in canine MCT in vitro, in vivo and ex vivo. We demonstrated that MCT cell lines were highly susceptible to reovirus as indicated by marked cell death, high production of progeny virus and virus replication. Reovirus induced apoptosis in the canine MCT cell lines with no correlation to their Ras activation status. In vivo studies were conducted using unilateral and bilateral subcutaneous MCT xenograft models with a single intratumoral reovirus treatment and apparent reduction of tumor mass was exhibited. Furthermore, cell death was induced by reovirus in primary canine MCT samples in vitro. However, canine and murine bone marrow-derived mast cells (BMCMC) were also susceptible to reovirus. The combination of these results supports the potential value of reovirus as a therapy in canine MCT but warrants further investigation on the determinants of reovirus susceptibility.
Collapse
Affiliation(s)
- Chung Chew Hwang
- Laboratory of Veterinary Internal Medicine, The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi, Japan
| | - Saori Umeki
- Laboratory of Veterinary Internal Medicine, The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi, Japan
| | - Masahito Kubo
- Laboratory of Veterinary Pathology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - Toshiharu Hayashi
- Laboratory of Veterinary Pathology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - Hiroshi Shimoda
- Laboratory of Veterinary Microbiology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - Masami Mochizuki
- Emerging Infectious Diseases, Joint Faculty of Veterinary Medicine, Kagoshima University, Kagoshima, Japan
| | - Ken Maeda
- Laboratory of Veterinary Microbiology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - Kenji Baba
- Yamaguchi University Animal Medical Center, Yamaguchi, Japan
| | - Hiroko Hiraoka
- Yamaguchi University Animal Medical Center, Yamaguchi, Japan
| | - Matt Coffey
- Oncolytics Biotech Inc., Calgary, Alberta, Canada
| | - Masaru Okuda
- Laboratory of Veterinary Internal Medicine, The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi, Japan
- Laboratory of Veterinary Internal Medicine, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
- Biomedical Science Center for Translational Research, The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi, Japan
| | - Takuya Mizuno
- Laboratory of Veterinary Internal Medicine, The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi, Japan
- Laboratory of Veterinary Internal Medicine, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
- Biomedical Science Center for Translational Research, The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi, Japan
- * E-mail:
| |
Collapse
|
9
|
Usher SG, Radford AD, Villiers EJ, Blackwood L. RAS, FLT3, and C-KIT mutations in immunophenotyped canine leukemias. Exp Hematol 2008; 37:65-77. [PMID: 18977066 DOI: 10.1016/j.exphem.2008.09.005] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2008] [Revised: 09/08/2008] [Accepted: 09/08/2008] [Indexed: 12/30/2022]
Abstract
OBJECTIVE To determine the frequency of FLT3, C-KIT, and RAS mutations in canine leukemia patients. MATERIALS AND METHODS Ethylenediamine tetra-acetic acid blood samples were recruited from dogs with suspected leukemia, categorized by quantitative and cytological evaluation and immunophenotyping. Flow cytometry was carried out using antibodies against CD3; CD3e; CD4; CD5; CD8; CD11a, b, c, and d; CD14; CD21; CD34; CD45 and 45RA; CD79a; CD90 (THY-1); major histocompatibility complex II; myeloperoxidase; MAC387; and neutrophil-specific antibody. Genomic DNA was extracted from whole blood and analyzed for mutations in N, H, and K-RAS, FLT3, and C-KIT genes by polymerase chain reaction and sequencing. RESULTS Fifty-seven (77.0%) of 74 samples submitted from dogs with suspected leukemia had cytologically and immunophenotypically confirmed leukemia. There were 36 (63.2%) acute leukemias, 16 (28.1%) chronic, 3 (5.3%) prolymphocytic, 1 natural killer cell, and 1 chronic leukemia undergoing blast transformation. N-RAS mis-sense mutations were identified in 14 (25%) dogs with acute myeloid (AML) or lymphoid (ALL) leukemia, and also in one dog in the leukemic phase of lymphoma. Mutations in K-RAS were found in two dogs with AML. There were no H-RAS mutations. FLT3 internal tandem duplications were identified in three dogs with ALL, and a mis-sense mutation was found in one dog with ALL. C-KIT mutations were identified in three dogs with AML. Sixty-one percent of dogs with acute leukemia harbored mutations in N/K-RAS, FLT3, or C-KIT. CONCLUSION RAS, FLT3, and C-KIT mutations, analogous to those found in human leukemia, occur commonly in acute canine leukemia.
Collapse
Affiliation(s)
- Suzanne G Usher
- Small Animal Teaching Hospital, University of Liverpool, The Leahurst Campus, Neston, Wirral, UK
| | | | | | | |
Collapse
|
10
|
De Maria R, Olivero M, Iussich S, Nakaichi M, Murata T, Biolatti B, Di Renzo MF. Spontaneous Feline Mammary Carcinoma Is a Model of HER2 Overexpressing Poor Prognosis Human Breast Cancer. Cancer Res 2005. [DOI: 10.1158/0008-5472.907.65.3] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Companion animal spontaneous tumors are suitable models for human cancer, primarily because both animal population and the tumors are genetically heterogeneous. Feline mammary carcinoma (FMC) is a highly aggressive, mainly hormone receptor–negative cancer, which has been proposed as a model for poor prognosis human breast cancer. We have identified and studied the feline orthologue of the HER2 gene, which is both an important prognostic marker and therapeutic target in human cancer. Feline HER2 (f-HER2) gene kinase domain is 92% similar to the human HER2 kinase. F-HER2–specific mRNA was found 3- to 18-fold increased in 3 of 3 FMC cell lines, in 1 of 4 mammary adenomas and 6 of 11 FMC samples using quantitative reverse transcription-PCR. Western blot showed that an anti-human HER2 antibody recognized a protein comigrating with the human p185HER2 in FMC cell lines. The same antibodies strongly stained 13 of 36 FMC archival samples. These data show that feline HER2 overexpression qualifies FMC as homologous to the subset of HER2 overexpressing, poor prognosis human breast carcinomas and as a suitable model to test innovative approaches to therapy of aggressive tumors.
Collapse
Affiliation(s)
- Raffaella De Maria
- 1Department of Animal Pathology, School of Veterinary Medicine, University of Turin, Grugliasco, and
| | - Martina Olivero
- 2Laboratory of Cancer Genetics and Comparative Oncology Center of the Institute for Cancer Research and Treatment, University of Turin, Candiolo, Turin, Italy; and
| | - Selina Iussich
- 1Department of Animal Pathology, School of Veterinary Medicine, University of Turin, Grugliasco, and
| | - Munekazu Nakaichi
- 3Department of Veterinary Surgery, Faculty of Agriculture, Yamaguchi University, Yamaguchi, and
| | - Tomoaki Murata
- 4Science Research Center, Yamaguchi University, Ube, Yamaguchi, Japan
| | - Bartolomeo Biolatti
- 1Department of Animal Pathology, School of Veterinary Medicine, University of Turin, Grugliasco, and
| | - Maria Flavia Di Renzo
- 2Laboratory of Cancer Genetics and Comparative Oncology Center of the Institute for Cancer Research and Treatment, University of Turin, Candiolo, Turin, Italy; and
| |
Collapse
|
11
|
Winkler S, Murua Escobar H, Günther K, Richter A, Dolf G, Schelling C, Bullerdiek J, Nolte I. The canine KRAS2 gene maps to chromosome 22. Anim Genet 2004; 35:350-1. [PMID: 15265080 DOI: 10.1111/j.1365-2052.2004.01136.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- S Winkler
- Center for Human Genetics, University of Bremen, Bremen, Germany
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Mayr B, Schaffner G, Reifinger M, Loupal G. K-ras protooncogene mutations in feline pancreatic adenocarcinomas. Vet Rec 2003; 153:468-9. [PMID: 14584578 DOI: 10.1136/vr.153.15.468] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Affiliation(s)
- B Mayr
- Institute for Animal Breeding and Genetics, Veterinary University, Veterinärplatz 1, A-1210 Vienna, Austria
| | | | | | | |
Collapse
|
13
|
Sulaimon SS, Kitchell BE. The Basic Biology of Malignant Melanoma: Molecular Mechanisms of Disease Progression and Comparative Aspects. J Vet Intern Med 2003; 17:760-72. [PMID: 14658711 DOI: 10.1111/j.1939-1676.2003.tb02513.x] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
Malignant melanoma (MM) is a life-threatening disease characterized by a highly aggressive biologic behavior in both humans and dogs. Despite improvements in diagnosis and patient care, most deaths from MM are due to metastases that are resistant to conventional treatment modalities. To ultimately reduce the mortality associated with metastatic disease, it is necessary to better define the fundamental molecular mechanisms of malignant tumor progression. The progression of disease is a consequence of the complex interactions between malignantly transformed cells and host factors. Characterization of the stages of tumor progression and the changes occurring in highly malignant cells is important for the development of effective treatment regimens. The dys-regulated molecular mechanisms of transformed melanocytes are presently being characterized. In this review, we summarize the current understanding of the molecular phases in the progression of MM, which include genetic instability, dysregulated proliferation of melanocytes, increased invasion and metastasis, and angiogenesis.
Collapse
Affiliation(s)
- Shola S Sulaimon
- Department of Veterinary Clinical Medicine, Veterinary Teaching Hospital, University of Illinois at Urbana-Champaign, Urbana, IL, USA
| | | |
Collapse
|
14
|
Affiliation(s)
- B Mayr
- Institute for Animal Breeding and Genetics, Veterinary University, Veterinarplatz I, A-1210 Vienna, Austria
| | | | | |
Collapse
|
15
|
Mayr B, Holzheu M, Schaffner G, Reifinger M. N-ras mutation in a canine lymphoma: short communication. Acta Vet Hung 2003; 51:91-4. [PMID: 12688129 DOI: 10.1556/avet.51.2003.1.8] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Lymphomas of dogs were investigated by molecular genetic methods. Regions of exon 1 and 2 of the N-ras gene, which harbours the mutation hot spots (codons 12, 13 and 61) were screened. A GGT [symbol: see text] GAT (glycine [symbol: see text] aspartic acid) mutation in codon 13 was present in a multicentric-type lymphoma of a 1-year-old male dog.
Collapse
Affiliation(s)
- B Mayr
- Institute for Animal Breeding and Genetics, Veterinary University, Veterinärplatz 1, A-1210 Vienna, Austria.
| | | | | | | |
Collapse
|
16
|
Mayr B, Schaffner G, Reifinger M, Zwetkoff S, Prodinger B. N-ras mutations in canine malignant melanomas. Vet J 2003; 165:169-71. [PMID: 12573607 DOI: 10.1016/s1090-0233(02)00245-9] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Affiliation(s)
- B Mayr
- Institute for Animal Breeding and Genetics, Veterinary University, Veterinärplatz 1, A-1210 Vienna, Austria.
| | | | | | | | | |
Collapse
|
17
|
Mayr B, Winkler G, Schaffner G, Reifinger M, Brem G. N-ras mutation in a feline lymphoma. Low frequency of N-ras mutations in a series of feline, canine and bovine lymphomas. Vet J 2002; 163:326-8. [PMID: 12090776 DOI: 10.1053/tvjl.2001.0691] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Burkhard Mayr
- Institute for Animal Breeding and Genetics, Veterinary University, Veterinärplatz 1, A-1210 Vienna, Austria.
| | | | | | | | | |
Collapse
|